Navigation Links
CSL Behring Recognized as a "Pioneer" By European Organisation for Rare Diseases (EURORDIS)
Date:3/1/2012

BRUSSELS, March 1, 2012 /PRNewswire/ -- CSL Behring is the recipient of a 2012 EURORDIS Award for its pioneering work in developing and manufacturing therapies used to treat rare and serious medical conditions. The global biotherapeutics company, which specializes in plasma-derived and recombinant therapies used to treat congenital bleeding disorders, immune deficiencies, hereditary angioedema and inherited respiratory disease, is a subsidiary of CSL Limited (ASX:CSL).

(Logo:  http://photos.prnewswire.com/prnh/20100914/PH63692LOGO )

One of the primary criteria for the award is a demonstrated commitment to providing access to therapies for people with rare diseases. The award was presented yesterday at the first EURORDIS Gala Dinner in the Hotel Le Plaza. "Solidarity," the theme of 2012 Rare Disease Day, focuses on the importance and the need for collaboration in the field of rare diseases.

"CSL Behring is honored and delighted to receive a 2012 EURORDIS Award," said Senior Vice President of Public Affairs Dennis Jackman. "This award is a reflection of our commitment to providing safe and effective therapies to improve the lives of patients with rare and serious medical conditions.  CSL Behring's commitment is further demonstrated in the company's growing investment in research and development, which has added to an extensive rare disease product portfolio, and in advanced manufacturing facilities and patient support."

CSL Behring received the National Organization for Rare Disorders 2011 Corporate Award for new treatments for rare diseases brought to market in the U.S.

About EURORDIS

EURORDIS is a non-governmental, patient-driven alliance of patient organisations and individuals active in the field of rare diseases, dedicated to improving the quality of life
'/>"/>

SOURCE CSL Behring
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. First Patient Screened in CSL Behring Global Phase I/III Study of Recombinant Single-Chain Factor VIII
2. CSL Behring Receives FDA Orphan Drug Designation for rVIIa-FP, a Novel Therapy in Development to Treat Hemophilia A and Hemophilia B Patients Who Have Inhibitors
3. CSL Behring Receives FDA Approval of Expanded Label on Berinert® for Self-administration and Treatment of Acute Laryngeal Attacks of Hereditary Angioedema
4. CSL Behring Seeks Proposals for Interlaken Leadership Awards, Supporting Innovative Research Into Neuroimmunology
5. CSL Behring Receives EU Orphan Drug Designations for rVIIa-FP for Hemophilia A and B Treatment
6. National Organization for Rare Disorders Presents CSL Behring With 2011 Corporate Award
7. CSL Behring Marks World Hemophilia Day with Coagulation Factor Donation to World Federation of Hemophilia
8. CSL Behring Medical Product Donation Helps Meet Critical Need for Ongoing Cholera Relief Effort in Haiti
9. CSL Behring Announces Completion of National Marketing Authorizations of Berinert® After MRP in 23 European Countries
10. CSL Behring Announces FDA Approval of Berinert(R), First and Only Therapy Approved for the Treatment of Acute Abdominal and Facial Attacks of Hereditary Angioedema in U.S.
11. CSL Behring Receives Orphan-Drug Exclusivity for RiaSTAP(TM), First and Only Approved Treatment of Acute Bleeding Episodes in Patients with Congenital Fibrinogen Deficiency
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , España, September 2, 2014 ... global de fibrilación atrial muestran agentes antitrombóticos no ... -- Las presentaciones de GARFIELD-AF ... sobre el tratamiento y los resultados de pacientes ... clínica diaria --    Los datos ...
(Date:9/2/2014)... , Spanien, September 2, 2014 ... Das auf dem ESC-Kongress 2014 präsentierte ... Behandlung und Behandlungsergebnisse von schlaganfallgefährdeten Patienten ... Die Daten der ... Patienten, einer innovativen und unabhängigen Forschungsinitiative ...
(Date:9/2/2014)... , September 2, 2014 ... CONGRESS 2014 provide insight into treatment and outcomes ... clinical practice --   Data from ... Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF), an innovative, ... prevention strategies for atrial fibrillation (AF) patients remain ...
Breaking Medicine Technology:Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 2Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 3Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 4Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 5Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 6Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 7Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 8Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 9Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 10Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 11Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 2Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 3Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 4Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 5Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 6Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 7Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 8Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 9Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 10Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 11Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 2Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 3Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 4Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 5Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 6Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 7Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 8Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 9
(Date:9/3/2014)... Washington, D.C. (PRWEB) September 03, 2014 ... issued by GM, Flood Law Group , a ... up to date with the latest information is extremely ... the recalls and is spreading awareness by sponsoring a ... help individuals learn about their legal right to financial ...
(Date:9/3/2014)... Houston, TX (PRWEB) September 03, 2014 7 ... day is sufficient to get people perfect abs within a ... 7 days and will experience the difference not only in ... their vital organs. This has caught the attention of HealthyandFitZone.com’s ... Day Ab TARGETED Solution review shows it is scientific, ...
(Date:9/3/2014)... (PRWEB) September 03, 2014 Health ... increases patient safety, decreases medical errors, and strengthens ... , To mark the important role health information ... IHS and others across the U.S. have joined ... Week , September 16-20, 2014. With the NHIT ...
(Date:9/3/2014)... Morris Psychological Group , PA ... depression on October 9, 2014 from 4:30-8:30 at ... 1,000 organizations nationwide will be hosting National Depression ... installations. After completing a screening, participants will receive ... can offer further evaluation and treatment if necessary. ...
(Date:9/2/2014)... New research reveals that unplanned births out-of-hospital in Norway ... in Acta Obstetricia et Gynecologica Scandinavica , a ... and Gynecology, indicate that young women who have given ... in remote areas are more likely to have unplanned ... newborns. , In 2013, close to 60,000 babies ...
Breaking Medicine News(10 mins):Health News:Flood Law Group Spreads Awareness in Wake of Most Recent GM Recall Announcement 2Health News:7 Day Ab TARGETED Solution: Review Examining Mike Shaun and Karen Hadsall’s Workout Program Released 2Health News:7 Day Ab TARGETED Solution: Review Examining Mike Shaun and Karen Hadsall’s Workout Program Released 3Health News:Innovative Healthcare Solutions (IHS) Celebrates National Health IT Week September, 15-19, 2014 2Health News:Screenings for Depression by Morris Psychological Group, October 9, 2014 from 4:30 to 8:30pm, Rockaway Townsquare Mall (Macy’s Court) 2Health News:Unplanned births out-of-hospital increases risk of infant mortality 2
... film to IDC 1600 Plus X-Series DR, ... Company,Ltd.) (TSX: IDL), the global leader in the ... that HealthPartners Medical Group,of Indiana and Michigan has ... a multi-specialty physician group with facilities in,Michigan City, ...
... WELLINGTON, Fla., June 24 The Quantum Group,(Amex: ... that The Quantum Group of,Companies, namely Renaissance Health ... (FMA) Annual Expo., The FMA represents more ... this annual meeting to provide members with exposure ...
... a Unique Way to Fight Common Illnesses, HOLLYWOOD, ... new web site, http://www.help2getbetter.com, and the sale,of ... household,medicine and fight common illnesses. What makes these sick ... use today, but come packaged,together conveniently in one- or ...
... IRVINE, Calif., June 24 SectorWatch.biz announces the,availability ... in the,news and driving markets today. MarketStats offers ... for investors to respond with,articles and opinions on ... Investors can view MarketStats by visiting: ...
... Services Region of the American Red Cross is facing ... requests of local hospitals. The,morning began with five of ... is zero O-, the universal blood type. In order,to ... the Region should,maintain a minimum three-day supply of all ...
... Easy-to-use formulations help broaden market penetration in China, ... (Amex:,ADL), ( http://www.amdl.com ), a leader in specialty ... anticipates,releasing during the 3rd quarter of 2008 two ... product line. In addition to its,high quality injectable ...
Cached Medicine News:Health News:HealthPartners Medical Group in Michigan City purchases IDC digital radiography system 2Health News:HealthPartners Medical Group in Michigan City purchases IDC digital radiography system 3Health News:The Quantum Group of Companies Exhibits at Statewide Medical Conference 2Health News:The Quantum Group of Companies Exhibits at Statewide Medical Conference 3Health News:Launch of help2getbetter.com Provides Convenience and Portability to Household Medicines 2Health News:SectorWatch.biz Issues MarketStats on Medical Products and Device Companies INCC, CMED, WX, MR and AOB 2Health News:AMDL's Goodnak(R) Anti-Aging Skin Care Line Soon Available in Capsule & Lotion Form 2
Double ended lasik spatula with flattened tip for lifting and smoothing the corneal flap. The sharp tip is useful to outline a previous flap in preparation for retreatment....
Rounded tip spatula with 20 gauge shaft. Black finish for reduced glare....
Triangular 0.5 mm angled tip with 4 mm flat surface. Round knurled handle with dull finish. Tip angle: 150o....
Double ended with 0.5 mm x 10 mm and 0.5 mm x 15 mm blades. Both blades gently curved. Square serrated handle with polished finish. Most popular size or model....
Medicine Products: